Interferon alpha 2B
1
Reactions 481 - 11 Dec 1993 ★ Interferon alpha 2B First report of incomplete Reiter’s disease: case report Incomplete Reiter’s syndrome was diagnosed in a 45-year- old man 4 months after he commenced treatment for chronic active hepatitis C with SC interferon-α2B [Intron-A ® ] 9 MU 3-times weekly. A 6-month course of interferon-α2B 6 MU 3-times weekly had previously been uneventful, but liver function abnormalities recurred 3 months later and treatment was restarted at 9 MU 3-times weekly. The patient presented after 1 month’s therapy with malaise, myalgia and depression, and interferon-α2B was reduced to 6 MU 3-times weekly. However, after 4 months’ treatment, keratoderma blennorrhagicum of the feet developed and circinate balanitis and numerous psoriasis-like patches were observed. Histocompatibility tests were positive for HLA B27 and skin biopsy specimens were consistent with pustular psoriasis. The man discontinued interferon-α2B, and after treatment with topical tar, salicylic acid and a steroid, his symptoms resolved within 4 weeks. Author comment: ‘Reiter’s syndrome consists of arthritis, urethritis, conjunctivitis, and distinctive mucocutaneous lesions. However, less than one third of patients demonstrate all these findings and thus are frequently designated as having incomplete Reiter’s syndrome . . . We present the first reported case of systemically administered interferon-α producing an incomplete form of Reiter’s syndrome.’ Cleveland MG, et al. Incomplete Reiter’s syndrome induced by systemic interferon alpha treatment. Journal of the American Academy of Dermatology 29: 788-789, Part 1, Nov 1993 - USA 800236758 1 Reactions 11 Dec 1993 No. 481 0114-9954/10/0481-0001/$14.95 Adis © 2010 Springer International Publishing AG. All rights reserved
Transcript of Interferon alpha 2B
Reactions 481 - 11 Dec 1993
★Interferon alpha 2B
First report of incomplete Reiter’s disease: casereport
Incomplete Reiter’s syndrome was diagnosed in a 45-year-old man 4 months after he commenced treatment for chronicactive hepatitis C with SC interferon-α2B [Intron-A®] 9 MU3-times weekly. A 6-month course of interferon-α2B 6 MU3-times weekly had previously been uneventful, but liverfunction abnormalities recurred 3 months later and treatmentwas restarted at 9 MU 3-times weekly.
The patient presented after 1 month’s therapy with malaise,myalgia and depression, and interferon-α2B was reduced to 6MU 3-times weekly. However, after 4 months’ treatment,keratoderma blennorrhagicum of the feet developed andcircinate balanitis and numerous psoriasis-like patches wereobserved. Histocompatibility tests were positive for HLA B27and skin biopsy specimens were consistent with pustularpsoriasis.
The man discontinued interferon-α2B, and after treatmentwith topical tar, salicylic acid and a steroid, his symptomsresolved within 4 weeks.
Author comment: ‘Reiter’s syndrome consists of arthritis,urethritis, conjunctivitis, and distinctive mucocutaneouslesions. However, less than one third of patients demonstrateall these findings and thus are frequently designated as havingincomplete Reiter’s syndrome . . . We present the first reportedcase of systemically administered interferon-α producing anincomplete form of Reiter’s syndrome.’Cleveland MG, et al. Incomplete Reiter’s syndrome induced by systemic interferonalpha treatment. Journal of the American Academy of Dermatology 29: 788-789,Part 1, Nov 1993 - USA 800236758
1
Reactions 11 Dec 1993 No. 4810114-9954/10/0481-0001/$14.95 Adis © 2010 Springer International Publishing AG. All rights reserved
